首页> 外文期刊>Trials >Statistical analysis plan for the PlAtelet Transfusion in Cerebral Haemorrhage (PATCH) trial: a multicentre randomised controlled trial
【24h】

Statistical analysis plan for the PlAtelet Transfusion in Cerebral Haemorrhage (PATCH) trial: a multicentre randomised controlled trial

机译:脑出血中PlAtelet输血(PATCH)试验的统计分析计划:一项多中心随机对照试验

获取原文
           

摘要

Background Use of antiplatelet therapy shortly before stroke due to spontaneous primary intracerebral haemorrhage (ICH) is associated with higher case fatality in comparison to ICH without prior antithrombotic drug use. The PlAtelet Transfusion in Cerebral Haemorrhage (PATCH) trial aimed to assess the effect of platelet transfusion in patients presenting with ICH while using antiplatelet therapy. The main hypothesis of PATCH was that platelet transfusion would reduce death or dependence by reducing ICH growth. Methods/Design PATCH was a multicentre prospective, randomised, open, blinded endpoint (PROBE) parallel group trial, conducted at 60 hospitals in The Netherlands, Scotland and France. Forty-one sites enrolled 190 patients with spontaneous supratentorial ICH aged ≥18 years, who had used antiplatelet therapy for ≥7 days preceding ICH, if Glasgow Coma Scale was ≥8. Participants were randomised (1:1, with a secure web-based system using permuted blocks, stratified by study centre and type of antiplatelet therapy pre-ICH) to receive either platelet transfusion within 6 hours of symptom onset and 90 minutes of diagnostic brain imaging, or standard care without platelet transfusion. The primary outcome was modified Rankin Scale (mRS) score assessed blind to treatment allocation at 3 months after ICH. Planned secondary outcomes included ICH growth on brain imaging performed approximately 24 hours after randomisation, survival at 3 months, disability at 3 months scored using the Amsterdam Medical Centre linear disability score, heterogeneity of treatment effect on mRS and ICH growth according to presence of the computed tomography angiography spot sign, causes of poor outcome, and cost-effectiveness. Safety outcomes were transfusion reactions, thromboembolic complications, and serious adverse events occurring during hospitalisation. This statistical analysis plan was written without knowledge of the unblinded data. Trial registration The trial was registered with the Netherlands Trial Register on 29 April 2008 ( NTR1303 ).
机译:背景与自发性原发性脑内出血(ICH)相比,卒中前不久使用抗血小板治疗与不使用抗血栓药物的ICH相比,病死率更高。脑出血PlAtelet输血(PATCH)试验旨在评估在使用抗血小板疗法的ICH患者中血小板输注的效果。 PATCH的主要假设是血小板输注将通过减少ICH的生长来减少死亡或依赖性。方法/设计PATCH是一项多中心前瞻性,随机,开放,盲目的终点(PROBE)平行组试验,在荷兰,苏格兰和法国的60家医院中进行。如果格拉斯哥昏迷量表≥8,则有190位年龄≥18岁的自发性宫上性ICH≥19岁的患者在ICH前≥7天接受了抗血小板治疗。参与者被随机分配(1:1,使用置换块的安全网络系统,由研究中心和ICH前抗血小板治疗的类型分层),以在症状发作6小时内和90分钟诊断性脑成像中接受血小板输注,或无需血小板输注的标准护理。主要结果是在ICH后3个月对治疗分配不知情的情况下对改良的Rankin量表(mRS)评分进行了评估。计划的次要结局包括随机分组后约24小时进行脑成像的ICH增长,3个月的生存率,使用Amsterdam Medical Center线性残疾评分对3个月的残疾评分,根据计算结果的存在对mRS和ICH生长的治疗效果的异质性断层扫描血管造影的斑点征兆,不良结局的原因和成本效益。安全结局是输血反应,血栓栓塞并发症和住院期间发生的严重不良事件。该统计分析计划是在不了解未盲目数据的情况下编写的。审判注册该审判已于2008年4月29日在荷兰审判注册(NTR1303)中注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号